Martin R Wilkins

List of Publications by Year in Descending Order

175 papers	10,088 citations	54 h-index	98 g-index
207 ext. papers	12,076 ext. citations	10.9 avg, IF	5.82 L-index

#	Paper	IF	Citations
175	Genetic and environmental determinants of diastolic heart function. **2022**, 1, 361-371		0
174	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. *Nature Communications*, **2021**, 12, 7104	17.4	1
173	Personalized Medicine for Pulmonary Hypertension:: The Future Management of Pulmonary Hypertension Requires a New Taxonomy. *Clinics in Chest Medicine*, **2021**, 42, 207-216	5.3	0
172	NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2021**, 77, 2040-2052	15.1	6
171	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. *Genome Medicine*, **2021**, 13, 80	14.4	11
170	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. *Annals of the American Thoracic Society*, **2021**, 18, 981-988	4.7	3
169	Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. *Chest*, **2021**, 160, 1442-1458	5.3	4
168	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. *EBioMedicine*, **2021**, 69, 103444	8.8	5
167	The application of 'omics' to pulmonary arterial hypertension. *British Journal of Pharmacology*, **2021** , 178, 108-120	8.6	5
166	Hypoxia-induced pulmonary hypertension-Utilizing experiments of nature. *British Journal of Pharmacology*, **2021**, 178, 121-131	8.6	14
165	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2021**, 57,	13.6	9
164	miR-150-PTPMT1-cardiolipin signaling in pulmonary arterial hypertension. *Molecular Therapy - Nucleic Acids*, **2021**, 23, 142-153	10.7	3
163	The pathophysiological role of novel pulmonary arterial hypertension gene. *European Respiratory Journal*, **2021**, 58,	13.6	6
162	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. *Communications Biology*, **2021**, 4, 1002	6.7	
161	Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH. *European Respiratory Journal*, **2021**,	13.6	6
160	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. *Pulmonary Circulation*, **2021**, 11, 20458940211052823	2.7	1
159	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 586-594	10.2	14

158	Whole-genome sequencing of patients with rare diseases in a national health system. *Nature*, **2020**, 583, 96-102	50.4	139
157	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. *Nature Communications*, **2020**, 11, 1185	17.4	28
156	Pulmonary hypertension: Proteins in the blood. *Global Cardiology Science & Practice*, **2020**, 2020, e202007	0.7	1
155	Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 575-585	10.2	46
154	A population-based phenome-wide association study of cardiac and aortic structure and function. *Nature Medicine*, **2020**, 26, 1654-1662	50.5	23
153	Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. *Circulation Genomic and Precision Medicine*, **2020**,	5.2	9
152	Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 224-239	10.2	34
151	Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. *European Respiratory Journal*, **2020**, 56,	13.6	1
150	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. *European Respiratory Journal*, **2020**, 55,	13.6	12
149	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	16
148	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. *European Respiratory Journal*, **2019**, 53,	13.6	17
147	Deep learning cardiac motion analysis for human survival prediction. *Nature Machine Intelligence*, **2019**, 1, 95-104	22.5	109
146	Human PAH is characterized by a pattern of lipid-related insulin resistance. *JCI Insight*, **2019**, 4,	9.9	36
145	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238	35.1	55
144	Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 668-676	4.1	10
143	Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. *Thorax*, **2019**, 74, 380-389	7.3	16
142	CLIC4/Arf6 Pathway. *Circulation Research*, **2019**, 124, 52-65	15.7	12
141	Clinical trial design and new therapies for pulmonary arterial hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	81

140	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. *Nature Communications*, **2018**, 9, 1416	17.4	182
139	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy. *European Respiratory Journal*, **2018**, 51,	13.6	68
138	Apoptosis Signal-Regulating Kinase 1 Inhibition in Pulmonary Hypertension. Too Much to ASK?. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 286-288	10.2	4
137	Fractal Analysis of Right Ventricular Trabeculae in Pulmonary Hypertension. *Radiology*, **2018**, 288, 386-395	25.5	10
136	Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension. *JACC Basic To Translational Science*, **2018**, 3, 176-186	8.7	24
135	Metabolomic Insights in Pulmonary Arterial Hypertension. *Advances in Pulmonary Hypertension*, **2018**, 17, 103-109	0.5	0
134	Recent advances in pulmonary arterial hypertension. *F1000Research*, **2018**, 7,	3.6	18
133	3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. *Circulation: Cardiovascular Imaging*, **2018**, 11, e007402	3.9	10
132	Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002087	5.2	33
131	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. *Chest*, **2017**, 151, 468-480	5.9	57
130	Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. *Radiology*, **2017**, 283, 381-390	20.5	114
129	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 717-726	35.1	62
128	Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development. *Journal of Internal Medicine*, **2017**, 282, 129-141	10.8	18
127	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. *Science Translational Medicine*, **2017**, 9,	17.5	144
126	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. *Circulation*, **2017**, 136, 2022-2033	16.7	75
125	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. *Circulation*, **2017**, 135, 460-475	16.7	96
124	Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. *Cardiovascular Research*, **2017**, 113, 276-287	9.9	11
123	Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 2078-87	9.4	83

122	Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. *Pharmacology & Therapeutics*, **2016**, 164, 195-203	13.9	28
121	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. *Journal of Heart and Lung Transplantation*, **2015**, 34, 348-55	5.8	11
120	The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. *Nature*, **2015**, 524, 356-60	50.4	85
119	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). *European Respiratory Journal*, **2015**, 45, 1293-302	13.6	175
118	Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency. *Pulmonary Circulation*, **2015**, 5, 466-72	2.7	60
117	Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. *Circulation Research*, **2015**, 116, 1680-90	15.7	65
116	Pathophysiology and treatment of high-altitude pulmonary vascular disease. *Circulation*, **2015**, 131, 582-90	15.7	70
115	-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders. *Circulation: Cardiovascular Genetics*, **2014**, 7, 920-9		20
114	Pulmonary hypertension: the value of experimental medicine in new drug development. *Pulmonary Circulation*, **2014**, 4, 149-50	2.7	
113	miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia. *Biochemical Journal*, **2014**, 462, 103-12	3.8	41
112	Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat. *Pulmonary Circulation*, **2014**, 4, 462-70	2.7	15
111	Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. *Pulmonary Circulation*, **2014**, 4, 669-78	2.7	14
110	Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. *Circulation*, **2014**, 129, 1770-80	16.7	35
109	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *New England Journal of Medicine*, **2013**, 369, 319-29	59.2	852
108	Update in pulmonary vascular diseases 2012. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 23-8	10.2	3
107	Definitions and diagnosis of pulmonary hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D42-50	15.1	1163
106	Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 294-302	10.2	126
105	Advancing clinical trial design in pulmonary hypertension. *Pulmonary Circulation*, **2013**, 3, 217-25	2.7	12

104	Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. *Pulmonary Circulation*, **2013**, 3, 100-7	2.7	30
103	Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. *Circulation*, **2013**, 128, 1214-24	16.7	86
102	Pulmonary Hypertension: Biomarkers. *Handbook of Experimental Pharmacology*, **2013**, 77-103	3.2	6
101	Pulmonary hypertension: the science behind the disease spectrum. *European Respiratory Review*, **2012**, 21, 19-26	9.8	61
100	Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. *Circulation Research*, **2012**, 110, 1423-34	15.7	63
99	Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. *Circulation*, **2012**, 126, 455-67	16.7	181
98	Atorvastatin in pulmonary arterial hypertension (APATH) study. *European Respiratory Journal*, **2012**, 40, 67-74	13.6	46
97	Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. *Journal of the American College of Cardiology*, **2011**, 58, 300-9	15.1	166
96	Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Chest*, **2011**, 140, 1284-1291	5.3	79
95	Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. *Human Mutation*, **2011**, 32, 1385-9	4.7	116
94	Mechanisms of disease: pulmonary arterial hypertension. *Nature Reviews Cardiology*, **2011**, 8, 443-55	14.8	472
93	Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. *European Respiratory Journal*, **2011**, 38, 1453-60	13.6	78
92	Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart*, **2011**, 97, 1054-60	5.1	125
91	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension **2011**, 1477-1485		
90	Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. *Circulation*, **2010**, 121, 2045-66	16.7	367
89	Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. *Circulation*, **2010**, 122, 2058-67	16.7	76
88	S98 Ventilatory efficiency in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: physiological differences and implications for disease-specific end-points. *Thorax*, **2010**, 65, A45-A46	7.3	
87	Simvastatin as a treatment for pulmonary hypertension trial. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 1106-13	10.2	93

86	Simvastatin and sildenafil combine to attenuate pulmonary hypertension. *European Respiratory Journal*, **2009**, 34, 948-57	13.6	46
85	Response to Letter Regarding Article, Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension *Circulation*, **2009**, 119,	16.7	1
84	Therapeutic targets in pulmonary arterial hypertension **2009**, 121, 69-88		71
83	Emerging concepts and translational priorities in pulmonary arterial hypertension. *Circulation*, **2008** , 118, 1486-95	16.7	119
82	Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. *Circulation*, **2008**, 117, 3020-30	16.7	184
81	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. *European Respiratory Journal*, **2008**, 32, 198-209	13.6	101
80	Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 534-41	10.2	115
79	Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 861-9	10.2	54
78	Treating acute myocardial infarction: something in the wind?. *Lancet, The*, **2007**, 370, 1461-2	40	4
77	Genetic association of the serotonin transporter in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 173, 793-7	10.2	81
76	Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. *Proteomics*, **2006**, 6, 2286-94	4.8	48
75	Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 105-13	10.2	266
74	cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2005**, 288, L103-15	5.8	60
73	Phosphodiesterase type 5 and high altitude pulmonary hypertension. *Thorax*, **2005**, 60, 683-7	7.3	66
72	Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 1292-7	10.2	301
71	Bosentan: profile report. *Drugs and Therapy Perspectives*, **2003**, 19, 5-6	1.5	
70	Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. *Circulation*, **2003**, 107, 234-7	16.7	91
69	Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. *Circulation*, **2003**, 107, 3230-5	16.7	205

68	Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 1396-402	10.2	93
67	Natriuretic peptide receptors and the heart. *British Heart Journal*, **2002**, 87, 314-5		18
66	Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. *Clinical Science*, **2002**, 102, 253-268	6.5	22
65	Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. *Clinical Science*, **2002**, 102, 253	6.5	12
64	What do we want from proteomics in the detection and avoidance of adverse drug reactions. *Toxicology Letters*, **2002**, 127, 245-9	4.4	17
63	Bosentan. *American Journal of Cardiovascular Drugs*, **2002**, 2, 343	4	1
62	Nitric oxide, phosphodiesterase inhibition, and adaptation to hypoxic conditions. *Lancet, The*, **2002**, 359, 1539-40	40	17
61	Developments in therapeutics for pulmonary arterial hypertension. *Minerva Cardioangiologica*, **2002**, 50, 175-87	1.1	2
60	Right ventricular hypertrophy secondary to pulmonary hypertension is linked to rat chromosome 17: evaluation of cardiac ryanodine Ryr2 receptor as a candidate. *Circulation*, **2001**, 103, 442-7	16.7	31
59	Genetic and molecular mechanisms of pulmonary hypertension. *Clinical Medicine*, **2001**, 1, 138-45	1.9	4
58	Sildenafil inhibits hypoxia-induced pulmonary hypertension. *Circulation*, **2001**, 104, 424-8	16.7	406
57	Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L1359-69	5.8	37
56	Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2000**, 278, L981-7	5.8	41
55	A gene for primary pulmonary hypertension. *Lancet, The*, **2000**, 356, 1207-8	40	10
54	NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. *Circulation*, **1999**, 99, 605-7	16.7	81
53	Genetic determination of cardiac mass in normotensive rats: results from an F344xWKY cross. *Hypertension*, **1999**, 33, 949-53	8.5	88
52	Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. *British Journal of Pharmacology*, **1998**, 124, 1455-62	8.6	53
51	Downregulation of natriuretic peptide C-receptor protein in the hypertrophied ventricle of the aortovenocaval fistula rat. *Cardiovascular Research*, **1997**, 36, 363-71	9.9	9

50	Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat. *British Journal of Pharmacology*, **1996**, 119, 943-8	8.6	6
49	Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. *British Journal of Pharmacology*, **1996**, 119, 1217-22	8.6	43
48	Adrenomedullin activity in chronically hypoxic rat lungs. *American Journal of Physiology - Heart and Circulatory Physiology*, **1996**, 271, H622-9	5.2	14
47	The regulation of pulmonary vascular tone. *British Journal of Clinical Pharmacology*, **1996**, 42, 127-31	3.8	9
46	Renal response to candoxatrilat in patients with heart failure. *Journal of the American College of Cardiology*, **1995**, 25, 1273-81	15.1	40
45	Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat. *Cardiovascular Research*, **1995**, 29, 768-74	9.9	6
44	Induction of nitric oxide synthase in cultured vascular smooth muscle cells: the role of cyclic AMP. *British Journal of Pharmacology*, **1994**, 112, 396-402	8.6	39
43	Identification of renal natriuretic peptide receptor subpopulations by use of the non-peptide antagonist, HS-142-1. *British Journal of Pharmacology*, **1994**, 113, 931-9	8.6	8
42	Inhibition of nitric oxide synthesis in vascular smooth muscle by retinoids. *British Journal of Pharmacology*, **1994**, 113, 1448-54	8.6	37
41	Effect of endopeptidase-24.11 inhibition and of atrial natriuretic peptide clearance receptor ligand on the response to rat brain natriuretic peptide in the conscious rat. *British Journal of Pharmacology* , **1993**, 110, 350-4	8.6	6
40	The natriuretic peptide family: turning hormones into drugs. *Journal of Endocrinology*, **1993**, 137, 347-59	4.7	31
39	Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease. *Biochemical Society Transactions*, **1993**, 21 (Pt 3), 673-8	5.1	4
38	Meta-iodobenzylguanidine (MIBG) scanning in the diagnosis of phaeochromocytoma. *Journal of Human Hypertension*, **1993**, 7, 353-6	2.6	3
37	Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. *Journal of Clinical Investigation*, **1993**, 92, 2702-12	15.9	60
36	Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat. *British Journal of Pharmacology*, **1992**, 107, 50-7	8.6	9
35	Effect of pharmacological manipulation of endogenous atriopeptin activity on renal function. *American Journal of Physiology - Renal Physiology*, **1992**, 262, F161-7	4.3	3
34	A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. *Clinical Autonomic Research*, **1992**, 2, 373-81	4.3	3
33	Hypotension induced by intravascular administration of nerve growth factor in the rat. *Clinical Science*, **1991**, 80, 565-9	6.5	7

32	Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. *American Journal of Physiology - Renal Physiology*, **1991**, 260, F602-7	4.3	6
31	Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 6465-9	11.5	55
30	Alternative mechanisms for atriopeptin prohormone processing by isolated perfused rat hearts. *Journal of Pharmacology and Experimental Therapeutics*, **1990**, 254, 228-35	4.7	1
29	Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation. *Journal of Clinical Investigation*, **1990**, 85, 1274-9	15.9	43
28	Atrial natriuretic factor. *Annals of Clinical Biochemistry*, **1989**, 26 (Pt 2), 115-8	2.2	4
27	Carbidopa does not affect the renal response to atrial natriuretic factor in man. *Clinical Science*, **1989**, 77, 281-5	6.5	6
26	Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factor in unextracted plasma.. *Clinical Chemistry*, **1989**, 35, 953-957	5.5	15
25	Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factor in unextracted plasma. *Clinical Chemistry*, **1989**, 35, 953-7	5.5	2
24	Effect of lower body positive pressure on blood pressure, plasma atrial natriuretic factor concentration, and sodium and water excretion in healthy volunteers and cardiac transplant recipients. *Cardiovascular Research*, **1988**, 22, 231-5	9.9	15
23	Urinary guanosine 3':5'-cyclic monophosphate but not tissue kallikrein follows the plasma atrial natriuretic factor response to acute volume expansion with saline. *Clinical Science*, **1988**, 75, 489-94	6.5	13
22	Raised concentrations of plasma atrial natriuretic peptides in cardiac transplant recipients. *British Medical Journal*, **1987**, 294, 122		2
21	Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. *British Journal of Clinical Pharmacology*, **1987**, 23, 311-5	3.8	38
20	Captopril reduces the renal response to intravenous atrial natriuretic peptide in normotensives. *Journal of Human Hypertension*, **1987**, 1, 47-51	2.6	11
19	Change in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis. *Clinical Science*, **1986**, 71, 157-60	6.5	73
18	Behçet's disease presenting as benign intracranial hypertension. *Postgraduate Medical Journal*, **1986**, 62, 39-41	2	19
17	Sodium transport across erythrocyte membranes in diabetes mellitus. *Diabetes Research*, **1986**, 3, 407-10		3
16	William Withering and digitalis, 1785 to 1985. *British Medical Journal*, **1985**, 290, 7-8		13
15	Stroke affecting young men after alcoholic binges. *British Medical Journal*, **1985**, 291, 1342		27

14	Effect of propranolol on thyroid homeostasis of healthy volunteers. *Postgraduate Medical Journal*, **1985**, 61, 391-4	2	7
13	The effect of propranolol on circulating thyroid hormone measurements in thyrotoxic and euthyroid subjects. *European Journal of Endocrinology*, **1985**, 108, 351-5	6.5	7
12	A placebo controlled comparison of the effects of pirenzepine and amitriptyline on the tyramine pressor test in healthy volunteers. *British Journal of Clinical Pharmacology*, **1985**, 19, 829-31	3.8	2
11	Dissociation of changes in sodium transport in erythrocytes from changes in blood pressure. *Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension*, **1985**, 3, S21-3		
10	Amiodarone and plasma digoxin levels. *Lancet, The*, **1984**, 1, 1180	40	
9	Beta-adrenoceptor blocking drugs and the elderly. *Journal of the Royal College of Physicians of London*, **1984**, 18, 42-5		5
8	Drug reactions and the poor metaboliser. *Lancet, The*, **1983**, 2, 110	40	3
7	Test for circulating Na+-K+ ATPase inhibitors. *Lancet, The*, **1983**, 1, 1219	40	
6	Responsiveness to beta-adrenergic receptor stimulation: the effects of age are cardioselective. *British Journal of Clinical Pharmacology*, **1982**, 14, 821-6	3.8	54
5	Side effects of benoxaprofen **1982**, 284, 1782-1783		2
4	Bayesian inference associates rare KDR variants with specific phenotypes in pulmonary arterial hypertension		3
3	Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH		4
2	Genetic and environmental determinants of diastolic heart function		1
1	A Systematic Review with Meta-analysis of Biomarkers for detection of Pulmonary Arterial Hypertension. *ERJ Open Research*,00009-2022	3.5	1